Community Connection: Ovarian Cancer Canada is looking for volunteers! Could you help?
OVdialogue – consider joining our team in the role of Peer Support Volunteer. Over a few hours each week, you would be part of a team that helps connect people, support conversations and are thought leaders for OVdialogue. This is your opportunity to give back to those who have/continue to support you through the tough times, share your unique experiences, and help celebrate successes. For more details of what this entails, please reach out to @Mfallis ([email protected]).
OVdialogue – consider joining our team in the role of Peer Support Volunteer. Over a few hours each week, you would be part of a team that helps connect people, support conversations and are thought leaders for OVdialogue. This is your opportunity to give back to those who have/continue to support you through the tough times, share your unique experiences, and help celebrate successes. For more details of what this entails, please reach out to @Mfallis ([email protected]).
Mirvetuximab soravtansine (MIRV)
Hello. Has anyone out there tried to obtain treatment with Mirvetuximab soravtansine (MIRV) in the USA? If so, how did you go about it? Currently, in Canada, it is only available by participating in drug trials. But one has to qualify, and while I have tested positive for the folate receptor, I don’t have what is considered “measurable disease”, (nodules and pleural effusions in the lungs don’t qualify). My understanding is that MERV is better than the standard of care, which for me, after a third recurrence and three lines of chemotherapy plus PARP inhibitor would be gemcitabine.
0
Comments
-
Hello @PaulineJ How do you feel about not being able to participate due to not having "measurable disease"? I did look this up as I had not heard about it before. I believe from what I read it is in a Phase II trial? Is that correct? I could not find what "measurable disease" means in this data. It would be interesting to know what they mean by that.
I did find this info from a link regarding it. Here it is:
"More patients on mirvetuximab soravtansine required dose reductions due to TEAEs (34%) vs those on chemotherapy (24%); dose delays occurred in 54% of patients on each arm. Treatment discontinuation rates were 9% with mirvetuximab soravtansine vs 16% with chemotherapy."
It also stated that blurred vision that was reversible is in 41% in all grades of OC.
If you did meet all requirements, do you know if it would be a fairly smooth process to get approval for it here in Canada?
It was a very interesting read for me, nonetheless and thank you for bringing it to the attention of everyone on the site.
Let us know how we can support you on your journey.
0
